The Effect of Linagliptin on Mitochondrial and Endothelial Function
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Investigators propose to examine the effect of 12 weeks of Linagliptin, a diabetes drug,
treatment on inflammation as well as vascular and mitochondrial function in diabetic
patients. Investigators hypothesize that Linagliptin will reduce the proinflammatory state,
improve endothelial function, increase the blood flow at the muscle microcirculation level
and improve mitochondrial function. In this study, investigators will perform tests that
evaluate the function of small and large blood vessels by employing ultrasound and laser
doppler techniques. In addition MRI scans that evaluate the mitochondrial function of the
lower extremity muscles at rest and during exercise will also be employed. Forty subjects
with Type 2 diabetes will be studied for twelve weeks and half of them will be randomly
assigned to receive linagliptin while the other half will receive placebo. All tests will be
performed at the beginning and the end of the study.